{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:54:57Z","timestamp":1794862497799,"version":"4.9.1"},"reference-count":39,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Prurigo nodularis (PN) is a chronic pruritic dermatosis with incompletely defined pathogenesis, and molecular data from East Asian populations are limited. We characterized the transcriptomic signatures of non-atopic PN in Korean patients to identify pathways linked to chronic itch and lesion persistence. RNA sequencing was performed on lesional and non-lesional skin from 17 PN patients and normal skin from 11 controls, followed by differential expression, functional enrichment, and correlation analyses. Lesional PN skin showed distinct transcriptional signatures with upregulation of Th22\/IL-22\u2013related genes and IL-22\u2013inducible epidermal stress markers (S100A7\/A8\/A9, SERPINB4, HRNR), along with keratinization genes (KRT6C, KRT16, KRT17). Itch severity correlated strongly (Spearman\u2019s \u03c1&gt;0.7) with IL-22\u2013inducible stress genes, IL4R, profibrotic mediators (WNT5A), JAK\u2013STAT regulators (JAK3, SOCS1\/3), neuromodulatory\/epidermal\u2013neural genes (TRPV3), and senescence markers (CDKN1A, CXCL8, PLAUR). Non-lesional skin showed intermediate expression patterns, consistent with subclinical inflammation. Despite the modest sample size and single-ethnicity design, these findings indicate that non-atopic PN in Korean patients is characterized by IL-22\u2013driven epidermal stress, fibroblast remodelling, neuroimmune signalling, and senescence programsprogrammes, highlighting therapeutic targets including IL-31RA, IL-4R\u03b1\/JAK1, antifibrotic and senescence-directed pathways.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2025-0169","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:37:01Z","timestamp":1779176221000},"source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive Transcriptomic Profiling of Nonatopic Prurigo Nodularis in Korean Patients Reveals Il-22\u2013driven Epidermal Stress and Neuro-immuno-fibrotic Remodelling"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0576-0474","authenticated-orcid":false,"given":"Hei Sung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Seob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"155624","doi-asserted-by":"crossref","unstructured":"Lotti T, Buggiani G, Prignano F. Prurigo nodularis and lichen simplex chronicus. Dermatol Ther 2008; 21: 42\u201346.","DOI":"10.1111\/j.1529-8019.2008.00168.x"},{"key":"155625","doi-asserted-by":"crossref","unstructured":"Brooks SG, Coscarella G, Yosipovitch G. Prurigo nodularis: a historic perspective. Clin Dermatol 2025; 43: 606\u2013609.","DOI":"10.1016\/j.clindermatol.2025.03.006"},{"key":"155626","doi-asserted-by":"crossref","unstructured":"Singam V, Patel KR, Silverberg JI. Association of prurigo nodularis and lichen simplex chronicus with hospitalization for mental health disorders in US adults. Arch Dermatol Res 2020; 312: 587\u2013593.","DOI":"10.1007\/s00403-020-02046-5"},{"key":"155627","doi-asserted-by":"crossref","unstructured":"Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32: 1059\u20131065.","DOI":"10.1111\/jdv.14570"},{"key":"155628","doi-asserted-by":"crossref","unstructured":"Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol 2020; 83: 1567\u20131575.","DOI":"10.1016\/j.jaad.2020.04.182"},{"key":"155629","doi-asserted-by":"crossref","unstructured":"Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L, et al. Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol 2023; 14: 1301817.","DOI":"10.3389\/fimmu.2023.1301817"},{"key":"155630","doi-asserted-by":"crossref","unstructured":"Rinaldi G. The itch-scratch cycle: a review of the mechanisms. Dermatol Pract Concept 2019; 9: 90\u201397.","DOI":"10.5826\/dpc.0902a03"},{"key":"155631","doi-asserted-by":"crossref","unstructured":"Kwatra SG, Pereira MP, Misery L, Mollanazar NK, Shah P, Wiggins S. Prurigo nodularis: disease burden, clinical features and approach to management. Br J Dermatol 2025; 193: 642\u2013652.","DOI":"10.1093\/bjd\/ljaf213"},{"key":"155632","doi-asserted-by":"crossref","unstructured":"Li W, Pi Y, Xu J. Association between atopic dermatitis and prurigo nodularis: a systematic review and meta-analysis. Int J Dermatol 2025; 64: 282\u2013286.","DOI":"10.1111\/ijd.17493"},{"key":"155633","doi-asserted-by":"crossref","unstructured":"Shao Y, Zhu Y, Xiao Z, Shen Y, Dai B, Tang H, et al. RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching. Exp Dermatol 2023; 32: 30\u201340.","DOI":"10.1111\/exd.14678"},{"key":"155634","doi-asserted-by":"crossref","unstructured":"Kim HS, Keum HL, Chung IY, Nattkemper L, Head CR, Koh A, et al. Characterization of a perturbed skin microbiome in prurigo nodularis and lichen simplex chronicus. J Invest Dermatol 2023; 143: 2082\u20132085.","DOI":"10.1016\/j.jid.2023.03.1669"},{"key":"155635","doi-asserted-by":"crossref","unstructured":"Sutaria N, Alphonse MP, Marani M, Parthasarathy V, Deng J, Wongvibulsin S, et al. Cluster analysis of circulating plasma biomarkers in prurigo nodularis reveals a distinct systemic inflammatory signature in African Americans. J Invest Dermatol 2022; 142: 1300\u20131308.","DOI":"10.1016\/j.jid.2021.10.011"},{"key":"155636","doi-asserted-by":"crossref","unstructured":"Parthasarathy V, Cravero K, Xu L, Deng J, Sun Z, Engle SM, et al. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: a cluster analysis. J Am Acad Dermatol 2023; 88: 1101\u20131109.","DOI":"10.1016\/j.jaad.2023.01.042"},{"key":"155637","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Guttman-Yassky E, Yosipovitch G, Wiegmann H, Metze D, Kim M, et al. Th2 mRNA gene expression analysis separates prurigo nodularis into two immune signature groups. J Eur Acad Dermatol Venereol 2025; 39: 1750\u20131759.","DOI":"10.1111\/jdv.20812"},{"key":"155638","doi-asserted-by":"crossref","unstructured":"Cornman HL, Manjunath J, Reddy SV, Adams J, Rajeh A, Samuel C, et al. Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation. Sci Rep 2024; 14: 8098.","DOI":"10.1038\/s41598-024-58013-x"},{"key":"155639","doi-asserted-by":"crossref","unstructured":"Ma F, Gharaee-Kermani M, Tsoi LC, Plazyo O, Chaskar P, Harms P, et al. Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab. J Allergy Clin Immunol 2024; 153: 146\u2013160.","DOI":"10.1016\/j.jaci.2023.07.005"},{"key":"155640","doi-asserted-by":"crossref","unstructured":"Tsoi LC, Hacini-Rachinel F, Fogel P, Rousseau F, Xing X, Patrick MT, et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol 2022; 149: 1329\u20131339.","DOI":"10.1016\/j.jaci.2021.10.004"},{"key":"155641","doi-asserted-by":"crossref","unstructured":"Belzberg M, Alphonse MP, Brown I, Williams KA, Khanna R, Ho B, et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization. J Invest Dermatol 2021; 141: 2208\u20132218.e2214.","DOI":"10.1016\/j.jid.2021.02.749"},{"key":"155642","doi-asserted-by":"crossref","unstructured":"Deng J, Parthasarathy V, Marani M, Bordeaux Z, Lee K, Trinh C, et al. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis. Front Med 2022; 9: 1022889.","DOI":"10.3389\/fmed.2022.1022889"},{"key":"155643","doi-asserted-by":"crossref","unstructured":"Brunner PM, Emerson RO, Tipton C, Garcet S, Khattri S, Coats I, et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. Allergy 2017; 72: 2017\u20132025.","DOI":"10.1111\/all.13223"},{"key":"155644","doi-asserted-by":"crossref","unstructured":"Moon S, Stasikowska-Kanicka O, W\u0105growska-Danilewicz M, Hawro M, Metz M, Maurer M, et al. Clinically uninvolved but not healthy-the skin of patients with atopic dermatitis is primed for itch and inflammation. J Eur Acad Dermatol Venereol 2024; 38: 1089\u20131100.","DOI":"10.1111\/jdv.19694"},{"key":"155645","doi-asserted-by":"crossref","unstructured":"Sutaria N, Alphonse MP, Roh YS, Choi J, Parthasarathy V, Deng J, et al. Cutaneous transcriptomics identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis. J Invest Dermatol 2022; 142: 2537\u20132540.","DOI":"10.1016\/j.jid.2022.02.010"},{"key":"155646","doi-asserted-by":"crossref","unstructured":"Gao Z, Dou Y, Zhao P, Wang CJ, Zhang J. Successful treatment of prurigo nodularis by dupilumab: report of 24 patients. Dermatology 2023; 239: 658\u2013663.","DOI":"10.1159\/000529965"},{"key":"155647","doi-asserted-by":"crossref","unstructured":"Patel JR, Joel MZ, Lee KK, Kambala A, Cornman H, Oladipo O, et al. Single-cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis. J Invest Dermatol 2024; 144: 1568\u20131578.","DOI":"10.1016\/j.jid.2023.12.021"},{"key":"155648","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly S, Tsou PS, Varga J. Senescence and tissue fibrosis: opportunities for therapeutic targeting. Trends Mol Med 2024; 30: 1113\u20131125.","DOI":"10.1016\/j.molmed.2024.05.012"},{"key":"155649","doi-asserted-by":"crossref","unstructured":"Lee YI, Shim JE, Kim J, Lee WJ, Kim JW, Nam KH, et al. WNT5A drives interleukin-6-dependent epithelial-mesenchymal transition via the JAK\/STAT pathway in keloid pathogenesis. Burns Trauma 2022; 10: tkac023.","DOI":"10.1093\/burnst\/tkac023"},{"key":"155650","doi-asserted-by":"crossref","unstructured":"Le TTT, Karmouty-Quintana H, Melicoff E, Le TTT, Weng T, Chen NY, et al. Blockade of IL-6 trans signaling attenuates pulmonary fibrosis. J Immunol 2014; 193: 3755\u20133768.","DOI":"10.4049\/jimmunol.1302470"},{"key":"155651","doi-asserted-by":"crossref","unstructured":"Hashimoto T, Nattkemper LA, Kim HS, Kursewicz CD, Fowler E, Shah SM, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol 2021; 30: 804\u2013810.","DOI":"10.1111\/exd.14279"},{"key":"155652","doi-asserted-by":"crossref","unstructured":"Chen W, Li Y, Steinhoff M, Zhang W, Buddenkotte J, Buhl T, et al. The PLAUR signaling promotes chronic pruritus. FASEB J 2022; 36: e22368.Chen W, Li Y, Steinhoff M, Zhang W, Buddenkotte J, Buhl T, et al. The PLAUR signaling promotes chronic pruritus. FASEB J 2022; 36: e22368.","DOI":"10.1096\/fj.202200079R"},{"key":"155653","doi-asserted-by":"crossref","unstructured":"Rukwied R, Weinkauf B, Main M, Obreja O, Schmelz M. Inflammation meets sensitization--an explanation for spontaneous nociceptor activity? Pain 2013; 154: 2707\u20132714.","DOI":"10.1016\/j.pain.2013.07.054"},{"key":"155654","doi-asserted-by":"crossref","unstructured":"Zhong W, Wu X, Zhang W, Zhang J, Chen X, Chen S, et al. Aberrant expression of histamine-independent pruritogenic mediators in keratinocytes may be involved in the pathogenesis of prurigo nodularis. Acta Derm Venereol 2019; 99: 579\u2013586.","DOI":"10.2340\/00015555-3150"},{"key":"155655","doi-asserted-by":"crossref","unstructured":"Steinhoff M, B\u00edr\u00f3 T. A TR(I)P to pruritus research: role of TRPV3 in inflammation and itch. J Invest Dermatol 2009; 129: 531\u2013535.","DOI":"10.1038\/jid.2008.440"},{"key":"155656","doi-asserted-by":"crossref","unstructured":"Cowan A, Kehner GB, Inan S. Targeting itch with ligands selective for \u03ba opioid receptors. Handb Exp Pharmacol 2015; 226: 291\u2013314.","DOI":"10.1007\/978-3-662-44605-8_16"},{"key":"155657","doi-asserted-by":"crossref","unstructured":"Nattkemper LA, Tey HL, Valdes-Rodriguez R, Lee H, Mollanazar NK, Albornoz C, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol 2018; 138: 1311\u20131317.","DOI":"10.1016\/j.jid.2017.12.029"},{"key":"155658","doi-asserted-by":"crossref","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021; 6: 402.","DOI":"10.1038\/s41392-021-00791-1"},{"key":"155659","doi-asserted-by":"crossref","unstructured":"Kershaw NJ, Murphy JM, Liau NPD, Varghese LN, Laktyushin A, Whitlock EL, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 2013; 20: 469\u2013476.","DOI":"10.1038\/nsmb.2519"},{"key":"155660","doi-asserted-by":"crossref","unstructured":"Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A. Suppressors of cytokine signaling (SOCS) proteins and JAK\/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 2011; 31: 980\u2013985.","DOI":"10.1161\/ATVBAHA.110.207464"},{"key":"155661","doi-asserted-by":"crossref","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 2015; 66: 311\u2013328.","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"155662","doi-asserted-by":"crossref","unstructured":"Weisshaar E, Szepietowski JC, Bernhard JD, Hait H, Legat FJ, Nattkemper L, et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase. J Eur Acad Dermatol Venereol 2022; 36: 453\u2013461.","DOI":"10.1111\/jdv.17816"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46140\/53937","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46140\/53938","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46140\/53939","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46140\/53937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:37:20Z","timestamp":1779176240000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2025-0169","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}